OOIR: Observatory of International Research

Papers

(The median citation count of Lupus Science & Medicine is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
2021 DORIS definition of remission in SLE: final recommendations from an international task force	140
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials	59
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies	39
Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to ac	37
Living with systemic lupus erythematosus in 2020: a European patient survey	36
Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review	31
Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis	30
Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria	30
SARS-CoV-2 vaccines in patients with SLE	29
Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data	28
Association between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysis	24
Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries	24
Phenotypical changes and clinical significance of CD4⁺/CD8⁺T cells in SLE	24
Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway	23
Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study	23
Herpes zoster in SLE: prevalence, incidence and risk factors	23
Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis	22
Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004–2015	22
Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis	21
Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus	21
LLDAS is an attainable treat-to-target goal in childhood-onset SLE	21
Associations of metabolic syndrome in SLE	19
Towards a practical management of fatigue in systemic lupus erythematosus	19
Discoid lupus erythematosus skin lesion distribution and characteristics in Black patients: a retrospective cohort study	17
Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinica	17

Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus	17
Safety, immunological effects and clinical response in a phase I trial of umbilical cord mesenchymal stromal cells in patients with treatment refractory SLE	17
Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004–2015	17
Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus	17
Clinical and histopathological features of myositis in systemic lupus erythematosus	16
Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes	16
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study	16
Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus	16
Hydroxychloroquine is associated with lower platelet activity and improved vascular health in systemic lupus erythematosus	16
LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almen	15
Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus	15
Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis	15
Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus	15
Adverse pregnancy outcomes in women with systemic lupus erythematosus: can we improve predictions with machine learning?	14
Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms	14
Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial	13
Infection hospitalisation in systemic lupus in Sweden	13
Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre	13
Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort	13
Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis	13
Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis	12
Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus	12
Absence of renal remission portends poor long-term kidney outcome in lupus nephritis	12
Hospitalisation for systemic lupus erythematosus associates with an increased risk of mortality in Australian patients from 1980 to 2014: a longitudinal, population-level, data linkage, cohort study	11
Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need	11
Activated low-density granulocytes in peripheral and intervillous blood and neutrophil inflammation in placentas from SLE pregnancies	11
Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the Medical Expenditure Panel Survey (MEPS) 2016–2018	11
Impact of severe infections in SLE: an observational study from the Spanish national registry	11
ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases	11
Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state f(unctional) MRI study	11
Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE	10
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research	10
Myocardial infarctions, subtypes and coronary atherosclerosis in SLE: a case–control study	10
Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme	10
Hydroxychloroquine availability during COVID-19 crisis and its effect on patient anxiety	10
LUPUS-BEST—treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial	10
Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: a meta-analysis of randomised controlled trials	10
Characteristics of cardiovascular autonomic dysfunction and association with quality of life in patients with systemic lupus erythematosus	10
The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients	10
Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR)	10
Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus	10
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial	10
Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis	10
Sirolimus versus tacrolimus for systemic lupus erythematosus treatment: results from a real-world CSTAR cohort study	9
Breastfeeding in women with rheumatic diseases	9
Gut microbiota in SLE: from animal models to clinical evidence and pharmacological perspectives	9
Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort	9
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials	9
Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed lupus nephritis	9
Anti-Müllerian hormone in African-American women with systemic lupus erythematosus	8

Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus	8
Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine	8
Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis	8
RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin	8
Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study	8
Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome	8
Central nervous system infections in patients with systemic lupus erythematosus: a systematic review and meta-analysis	8
Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial	8
Hydroxychloroquine treatment in European patients with lupus erythematosus: dosing, retinopathy screening and adherence	8
Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE	8
One-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria	8
Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic scler	8
Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks	8
Infertility in systemic lupus erythematosus: what rheumatologists need to know in a new age of assisted reproductive technology	8
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE	8
Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE	8
Nailfold capillary scleroderma pattern may be associated with disease damage in childhood-onset systemic lupus erythematosus: important lessons from longitudinal follow-up	8
Gender differences in SLE: report from a cohort of 417 Caucasian patients	7
Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study	7
Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus	7
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus	7
Discovery of NEU1 as a candidate renal biomarker for proliferative lupus nephritis chronicity	7
Combining C reactive protein and serum albumin to predict 90-day mortality in systemic lupus erythematosus with serious community-acquired infections	7
Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response	7
Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study	7
Improving patient pathways for systemic lupus erythematosus: a multistakeholder pathway optimisation study	7
Correction: 2021 DORIS definition of remission in SLE: final recommendations from an international task force	7
Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study	7
Cutaneous lupus concerns from the patient perspective: a qualitative study	7
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network	6
Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state	6
Depression, stigma and social isolation: the psychosocial trifecta of primary chronic cutaneous lupus erythematosus, a cross-sectional and path analysis	6
Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development	6
Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study	6
Molecular signatures of intrarenal complement receptorsC3AR1andC5AR1correlate with renal outcome in human lupus nephritis	6
Enhanced medullary and extramedullary granulopoiesis sustain the inflammatory response in lupus nephritis	6
Rheumatologists’ perspective on hydroxychloroquine guidelines	6
Role of autoantibodies and blood–brain barrier leakage in cognitive impairment in systemic lupus erythematosus	6
Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupus	6
Molecular endotypes of type 1 and type 2 SLE	5
Evaluation of structured data from electronic health records to identify clinical classification criteria attributes for systemic lupus erythematosus	5
Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases	5
Case series of anifrolumab for treatment of cutaneous lupus erythematosus and lupus-related mucocutaneous manifestations in patients with SLE	5
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE wit	5
Lupus spectrum ambiguity has long-term negative implications for patients	5
Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study	5
Risk factors for changes in carotid intima media thickness and plaque over 5 years in women with systemic lupus erythematosus	5
Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus	5
Cross-sectional study of the effects of self-efficacy on fatigue and pain interference in black women with systemic lupus erythematosus: the role of depression, age and education	5
Treatment patterns in paediatric and adult patients with SLE: a retrospective claims database study in the USA	5
Transcription factor Fli-1 impacts the expression of CXCL13 and regulates immune cell infiltration into the kidney in MRL/lpr mouse	5
Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis	5
Clinical associations of cognitive dysfunction in systemic lupus erythematosus	5
A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus	5
Association of one-point glucocorticoid-free status with chronic damage and disease duration in systemic lupus erythematosus: a cross-sectional study	5
Mer-tyrosine kinase: a novel susceptibility gene for SLE related end-stage renal disease	4
Quick Systemic Lupus Activity Questionnaire (Q-SLAQ): a simplified version of SLAQ for patient-reported disease activity	4
Intermuscular adipose tissue in patients with systemic lupus erythematosus	4
Lupus pathogenesis and autoimmunity are exacerbated by high fat diet-induced obesity in MRL/lpr mice	4
Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis	4
Efficacy and safety of rituximab biosimilar in refractory lupus	4
Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients	4
Urine proteomic insights from the belimumab in lupus nephritis trial	4
Prevention and partial reversion of the lupus phenotype in ABIN1[D485N] mice by an IRAK4 inhibitor	4
Development and implementation of a virtual Lupus Patient Education Event during the COVID-19 pandemic	4
Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132	4
State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus	4
Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies	4
Impact of pregnancy in patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: case series and literature review	4
Vitamin D level in patients with systemic lupus erythematosus: its relationship to disease course and bone mineral density	4
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature	4
Remission of lupus nephritis: the trajectory of histological response in successfully treated patients	4
Low-dose belimumab for patients with systemic lupus erythematosus at low disease activity: protocol for a multicentre, randomised, double-blind, placebo-controlled clinical trial	4
Immune gene expression and functional networks in distinct lupus nephritis classes	4
Clinical outcome in patients with suspected inflammatory neuropsychiatric lupus treated with immunosuppression: an observational cohort study	4
Intracellular homocysteine metabolites in SLE: plasma S-adenosylhomocysteine correlates with coronary plaque burden	4
CD4⁺T-cell cooperation promoted pathogenic function of activated naïve B cells of patients with SLE	4
Vaginal microbiota affects urinary tract infection risk in women with systemic lupus erythematosus: a pilot cross-sectional study from Thailand	4
Targeted multiomics in childhood-onset SLE reveal distinct biological phenotypes associated with disease activity: results from an explorative study	4
Scleroderma-like capillaroscopic pattern in SLE is not a sign of overlap syndrome in both adults and children	4

Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus	4
Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis	4
Utility of the ACR-1997, SLICC-2012 and EULAR/ACR-2019 classification criteria for systemic lupus erythematosus: a single-centre retrospective study	4
Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis	4
Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards	4
Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort	4
Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial	3
Coping with systemic lupus erythematosus in patients’ words	3
ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies	3
Social Factors, Epigenomics and Lupus in African American Women (SELA) Study: protocol for an observational mechanistic study examining the interplay of multiple individual and social factors on lupus	3
Systemic Lupus Erythematosus Risk Probability Index: ready for routine use? Results from a Chinese cohort	3
Prevalence of systemic lupus erythematosus-related symptoms assessed by using the Connective Tissue Disease Screening Questionnaire in a large population-based cohort	3
Association of COVID-19 pandemic-related concern and health routine changes with functioning among individuals with systemic lupus erythematosus	3
Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study	3
Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity	3
Characteristics and renal survival of patients with lupus nephritis with glomerular immunoglobulin G₄deposition: a single-centre retrospective analysis	3
A better self-efficacy is predictive of better health-related quality of life (HRQoL) in patients with systemic lupus erythematosus: data from the Almenara Lupus Cohort	3
Study of common hypertriglyceridaemia genetic variants and subclinical atherosclerosis in a group of women with SLE and a control group	3
Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: a systematic review and meta-analysis of randomised trials	3
Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE	3
Insight into intraindividual variability across neuropsychological tests and its association with cognitive dysfunction in patients with lupus	3
Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis	3
Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model	3
Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic	3
Personalised therapy during preconception and gestation in SLE: usefulness of 6-mercaptopurine metabolite levelswith azathioprine	3
Different indirect immunofluorescence ANA substrate performance in a diagnostic setting of patients with SLE and related disorders: retrospective review and analysis	3
Autoantibody-based subgroups and longitudinal seroconversion in juvenile-onset systemic lupus erythematosus	3
Human leucocyte antigens profiling in Malay female patients with systemic lupus erythematosus: are we the same or different?	3
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE	3